Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0DH1H
|
||||
| Former ID |
DIB015527
|
||||
| Drug Name |
CCT-241533
|
||||
| Synonyms |
CCT-241533; Chk2 inhibitors (cancer); Chk2 inhibitors (cancer), Cancer Research Technology
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Investigative | [1] | ||
| Company |
Cancer Research Technology Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H27FN4O4
|
||||
| InChI |
InChI=1S/C23H27FN4O4/c1-23(2,30)15-10-25-11-17(15)27-21-13-8-19(31-3)20(32-4)9-16(13)26-22(28-21)14-7-12(24)5-6-18(14)29/h5-9,15,17,25-26,30H,10-11H2,1-4H3,(H,27,28)/b22-14-/t15-,17-/m1/s1
|
||||
| InChIKey |
IXTQNANZDPZION-GSOOIIRJSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Serine/threonine-protein kinase Chk2 | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cell cycle | ||||
| p53 signaling pathway | |||||
| HTLV-I infection | |||||
| Pathway Interaction Database | ATM pathway | ||||
| FOXM1 transcription factor network | |||||
| p53 pathway | |||||
| PLK3 signaling events | |||||
| Reactome | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | ||||
| G2/M DNA damage checkpoint | |||||
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | |||||
| WikiPathways | DNA Damage Response | ||||
| ATM Signaling Pathway | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Integrated Cancer pathway | |||||
| Cell Cycle | |||||
| miRNA Regulation of DNA Damage Response | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8044). | ||||
| REF 2 | CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors. Cancer Res. 2011 Jan 15;71(2):463-72. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.